Rethinking Executive Pay

Authored by David Hobbs, Senior Editor, Criticaleye

As the economic environment tightens, the pressure on remuneration committees looks set to intensify. Katherine Savage, People Advisory Services Partner at EY tells David Hobbs how they can create pay policies that are fair, balanced and reflective of a company’s performance.

Key points include:

- The need for executive pay restraint in the current climate
- Ensuring senior rewards are aligned with that of the wider workforce
- The restriction on businesses that received government support
- The view from regulators and central banks
- The potential for the pandemic to accelerate change around ESG

Share this with your Community





Click here to download this insight

DOWNLOAD INSIGHT



Related Insights

Read, watch & listen to some of the latest thought leadership from our Community.


The Future of Executive Leadership and High Performance

Andrew Darfoor, SID, Post Office & Board Mentor at Criticaleye, and Jodene Young, Chief People Officer at the National Physical Laboratory (NPL), join Bridgette Hall, Senior Editor at Criticaleye, for a discussio...


Click here to download this insight

Giving Back as a Non-executive Director

Following a growth-laden five years as CEO of IRIS Software Group, Elona Mortimer-Zhika is now enjoying a burgeoning non-executive career. In this interview with Criticaleye’s Jacob Ambrose Willson, she explain...


Cyber Resilience — How Secure Are You, Really? (ft. Jon Rigby)

Jon Rigby CBE, Senior Cyber Advisor and former Chief Cyber Officer at Liberty Specialty Markets, joins Jacob Ambrose Willson, Senior Editor at Criticaleye, to explore what it truly takes for organisations to build cy...


1 2 3 4 5 6 7 8 9 10
Displaying 1 to 3 of 206




Hitachi Solutions CrowdStrike NATS E.ON UK Southern Water NatWest Group Canaccord Genuity Group Inc Lightsource bp London Stock Exchange Group LACE Partners AlixPartners Mayborn Group Rolls-Royce Aldermore Group Global Payments Stream Drax Group plc Legal & General GlaxoSmithKline plc British Land